Cephalosporin derivatives

US5668284A · kind A · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Choung U. Kim · Redwood City, US
• Peter F. Misco · Syracuse, US
• John A. Wichtowski · Saint Albans, US
• Yasutsugu Ueda · Clinton, US
• Thomas W. Hudyma · Durham, US
• John D. Matiskella · Wallingford, US
• Stanley D'Andrea · Middletown, US
• Shelley E. Hoeft · Middletown, US
• Raymond F. Miller · Killingworth, US
• Muzammil M. Mansuri · Lexington, US
• Joanne J. Bronson · Madison, US

Key dates

• Filing date: May 8, 1996
• Grant date: Sep 16, 1997
• Expiry date: May 8, 2016

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl, pyridyl or benzthiazolyl group; R.sup.1 is selected from certain optionally substituted aliphatic, aromatic, arylaliphatic or sugar moieties and R.sup.2 and R.sup.3 are each independently hydrogen, alkyl or aminoalkylcarbonylamino are gram-positive antibacterial agents, especially useful in the treatment of infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA).